ViroPharma phase 1b HCV-796 study shows lower hepatitis C levels in patients

By Jennifer Chiou

New York, Nov. 10 - ViroPharma Inc. announced positive preliminary results from a phase 1b study with HCV-796, an orally dosed hepatitis C (HCV) viral polymerase inhibitor.

HCV-796 is in co-development with Wyeth Pharmaceuticals.

"With our partners at Wyeth, we have now demonstrated anti-HCV activity with HCV-796, the only non-nucleoside polymerase inhibitor to have positive clinical antiviral data," ViroPharma chief scientific officer Colin Broom said in a news release.

"This potentially opens up new treatment possibilities for patients suffering from the disease. These new data suggest that HCV-796 has a good tolerability profile, favorable pharmacokinetics and the potential to improve on the level of virologic response across multiple HCV genotypes, including genotype 1, which is the most common strain in the U.S. and the least responsive to currently available therapies."

The randomized, double blind, placebo-controlled study of HCV-796 tested the safety and tolerability of ascending multiple oral drug doses of HCV-796.

ViroPharma and Wyeth said they expect to have data on antiviral activity pharmacokinetics and tolerability of the drug in the second quarter of 2006.

Based in Exton, Pa., ViroPharma develops and markets drugs focused on viral diseases, including cytomegalovirus and hepatitis C.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.